We provide evidence that emerging drugs that target protein products of PCSK9, APOB and LPA are unlikely to impact upon glycemic status, and in that regard, may have advantages over statins for LDL-C lowering and prevention of CAD. The gene discussed is LPA; the disease is coronary artery disorder.